Everence Capital Management Inc. Acquires Shares of 8,150 Exelixis, Inc. (NASDAQ:EXEL)

Everence Capital Management Inc. bought a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) during the 4th quarter, Holdings Channel reports. The firm bought 8,150 shares of the biotechnology company’s stock, valued at approximately $271,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC grew its holdings in Exelixis by 37.2% during the 4th quarter. GAMMA Investing LLC now owns 4,129 shares of the biotechnology company’s stock worth $137,000 after acquiring an additional 1,119 shares during the last quarter. Retirement Systems of Alabama raised its stake in shares of Exelixis by 24.6% in the third quarter. Retirement Systems of Alabama now owns 911,497 shares of the biotechnology company’s stock worth $23,653,000 after acquiring an additional 180,021 shares during the last quarter. Tri Ri Asset Management Corp acquired a new position in shares of Exelixis during the third quarter worth approximately $4,396,000. Tidal Investments LLC grew its stake in shares of Exelixis by 2.3% during the third quarter. Tidal Investments LLC now owns 36,366 shares of the biotechnology company’s stock valued at $944,000 after purchasing an additional 823 shares during the last quarter. Finally, Sanctuary Advisors LLC increased its holdings in shares of Exelixis by 42.7% in the third quarter. Sanctuary Advisors LLC now owns 39,261 shares of the biotechnology company’s stock valued at $1,019,000 after purchasing an additional 11,757 shares in the last quarter. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Exelixis Trading Up 3.0 %

NASDAQ:EXEL opened at $34.21 on Wednesday. Exelixis, Inc. has a 1 year low of $19.20 and a 1 year high of $36.97. The stock has a 50-day moving average price of $34.78 and a two-hundred day moving average price of $28.63. The stock has a market cap of $9.77 billion, a price-to-earnings ratio of 21.93, a PEG ratio of 0.89 and a beta of 0.53.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.04. The business had revenue of $539.50 million during the quarter, compared to analyst estimates of $490.31 million. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. Exelixis’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.10 EPS. Sell-side analysts forecast that Exelixis, Inc. will post 1.69 earnings per share for the current year.

Insider Buying and Selling

In other Exelixis news, EVP Dana Aftab sold 1,162 shares of the stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total transaction of $36,486.80. Following the completion of the transaction, the executive vice president now owns 498,945 shares in the company, valued at approximately $15,666,873. This represents a 0.23 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the business’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $36.67, for a total value of $2,200,200.00. Following the completion of the sale, the executive vice president now owns 486,059 shares in the company, valued at approximately $17,823,783.53. This trade represents a 10.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 314,736 shares of company stock worth $10,849,110 over the last ninety days. Company insiders own 2.85% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Guggenheim upped their price objective on Exelixis from $33.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday. Stephens raised their price target on Exelixis from $23.00 to $29.00 and gave the company an “equal weight” rating in a report on Wednesday, October 30th. Royal Bank of Canada reiterated an “outperform” rating and issued a $34.00 price objective on shares of Exelixis in a research report on Wednesday, October 30th. Wells Fargo & Company upped their target price on shares of Exelixis from $32.00 to $36.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. Finally, HC Wainwright reiterated a “buy” rating and set a $29.00 price target on shares of Exelixis in a research report on Wednesday, September 18th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Exelixis has an average rating of “Moderate Buy” and a consensus target price of $33.00.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.